NIH-funded research NIH-funded research

Peripheral nerve stimulation for chronic neuropathic pain in a new mechanistic trial

Official title: Mechanisms of Action of Peripheral Nerve Stimulation for the Treatment of Chronic Neuropathic Pain

Funded at Stanford University · NIH-11579998 · Data updated 2026-11-12

A study at Stanford tests whether a painless-sounding electrical nerve treatment helps people with long-standing neuropathic pain when added to standard care.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionStanford University
NIH-funded
Lab location1 site (Stanford, United States)
Project startSeptember 20, 2023
Project endAugust 31, 2028
Funding year2026
Award (this year)$2,054,560
NIH project number4RM1NS128956-02
Project IDNIH-11579998 on NIH RePORTER

Who could benefit from this research

Could help

Adults with lower extremity chronic neuropathic pain who are candidates for standard medical management and may opt into PNS therapy.

Less likely to help

Patients with pain conditions not driven by peripheral nerve signals or who are not suitable for PNS may see little to no benefit.

What this research studies

This project explores how percutaneous peripheral nerve stimulation (PNS) relieves chronic neuropathic pain by examining the nervous system's response to treatment. Participants with lower extremity chronic neuropathic pain will be randomized to receive either conventional medical management alone or in combination with PNS, with monthly remote check-ins over a year. The team will use quantitative sensory testing and advanced imaging to uncover how PNS changes nerve firing, pain signaling, and central sensitization, aiming to identify predictors of who benefits. The study builds on prior PNS work and includes clinical trials, psychological assessments, and measurements of pain processing to map mechanisms and outcomes.

Why it matters

Potential benefit: If successful, the findings could improve how PNS is used to treat chronic neuropathic pain and help tailor therapy to patients most likely to benefit.

How similar studies have gone: Prior studies with PNS have shown symptom relief in selected patients, but this project adds mechanistic insight to optimize use.

Where this research is happening

  • Stanford University
    Stanford, United States
    Active

Researchers

  • Principal investigator: Hah, Jennifer — Stanford University
  • Study coordinator: Hah, Jennifer

Related research

Other NIH-funded projects on the same topics.

  • Keratinocytes and nerve pain in chemotherapy patients

    A study tests a new approach to reduce painful nerve damage from chemotherapy by targeting skin cells called keratinocytes.

    NIH research Medical College of Wisconsin · Milwaukee, United States · NIH-11447051

  • High-frequency brain stimulation for trigeminal neuropathic pain

    A large, multi-site trial tests a non-invasive brain stimulation method to relieve chronic facial nerve pain for adults who have not found relief from other treatments.

    NIH research University of California, San Francisco · San Francisco, United States · NIH-11435301

  • Programmable lithium-delivery devices for pain relief without motor loss

    A new bioelectronic system uses a safe lithium source and AI-powered control to deliver targeted pain relief for neuropathic pain, aiming to spare motor function.

    NIH research University of Chicago · Chicago, United States · NIH-11429988

  • Glial-nerve conversations in neuropathic pain and diabetes

    This grant looks at how supportive brain and nerve cells communicate with pain-sensing neurons to understand and reduce chronic nerve pain in people.

    NIH research Duke University · Durham, United States · NIH-11420907

  • Parmodulins with Low Abuse Potential for Neuropathic Pain

    A new class of pain medicines called parmodulins is being studied to help people with nerve-pain pain without high abuse risk.

    NIH research Function Therapeutics, INC. · Milwaukee, United States · NIH-11415152

  • Nonopioid peptide therapy to reset nerve pain biology

    A new, first‑in‑class peptide medicine (ASCT‑83) is being developed to target the biology of neuropathic pain in adults, with early human testing planned after successful preclinical work.

    NIH research Alcamena Stem Cell Therapeutics, LLC · Baltimore, UNITED STATES · NIH-11387927

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.